2023.09.12
Axcelead will be exhibiting at upcoming Discovery On Target 2023 in Boston. Visit us at Booth #200 to learn how we can empower your drug discovery. Our team looks forward to meeting you there! Date: September 25 – 28, 2023Venue: Sheraton BostonBooth No. #200 ■Presentation in symposiumAxcelead will also be presenting at the Strategies for Targeting Kinases Symposium […]
2023.08.23
PDF Axcelead Drug Discovery Partners Inc. (“Axcelead DDP”) is pleased to announce that it has been honored with the Startup Encouragement Award at the 6th Japan Medical Research and Development Grand Prize Award Ceremony presented by the Japanese Cabinet Office. The Japan Medical Research and Development Grand Prize aims to recognize and celebrate remarkable achievements […]
2023.07.06
PDF Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa, Kanagawa; President and CEO: Nobuhiko Yamada; hereinafter, “Axcelead DDP”) and IQVIA Solutions Japan Co., Ltd. (Headquarters: Minato-ku, Tokyo; President: Fumihiko Ugajin; hereinafter, “IQVIA”) have entered discussions regarding a collaboration on genomic drug discovery support utilizing IQVIA’s genetic database, the IQVIA Genome Wide Study Platform (hereinafter, “GWSP”). GWSP […]
2023.05.16
Axcelead will be exhibiting at upcoming BIO International Convention 2023 in Boston. Visit us at Japan Pavilion Booth #1353 to learn how we can empower your drug discovery. Our team looks forward to meeting you there! Date: Monday, June 5, 2023 – Thursday, June 8, 2023Venue: Boston Convention & Exhibition Center – Boston, MA Japan […]
2023.05.12
Join us for our luncheon seminar and visit us at booth #8 during the 43rd Workshop of the Korean Society of Nonclinical Study in Suwon. Luncheon seminar #2「Driving innovative drug discovery through Axcelead integrated platform」 Date: 12:10~12:30 on Friday, May 26th, 2023Location: Convention Hall 3, Suwon Convention CenterSpeaker: Dr. Takahiro Tanaka (Director, Sales, Axcelead Drug […]
2023.04.20
As a global CRDMO (Contract Research, Development and Manufacturing Organization), Axelead, a holding company, will be fully developing its overseas business in the future. Dr. Ikeura answers questions from the media. （April 13, 2023） Read full article PHARMA JAPAN Posted on April 13, 2023 [LICENSE NO. 20230417_02] Jiho Inc. permits the use of articles.
2023.04.13
PDF Kanagawa, Japan, April 13, 2023 — We announced that it has decided to make the following changes to its President & CEO effective May 1, 2023. １．Details of Changes in Positions (as of May 1, 2023) Name Current Position New Position Yoshinori Ikeura President & CEO Chairperson, Member of the Board Nobuhiko Yamada COO […]
2023.03.10
PDF Kyoto and Kanagawa, Japan, March 10, 2023 — Orizuru Therapeutics Inc. (“OZTx”) and Axcelead Drug Discovery Partners, Inc (“Axcelead DDP”) have entered into a collaboration for drug discovery support services related to iPS cells. OZTx has a broad range of technology and expertise in the field of iPS cells, and has skilled researchers that […]
2023.02.20
PDF Tokyo, Japan, February 20, 2023 — Teijin Limited and Axcelead, Inc. jointly announced today their basic agreement on a capital and business alliance to establish a joint venture company that will primarily utilize the drug discovery research capabilities of Teijin Pharma Limited, the Teijin Group’s core healthcare company. Teijin and Axcelead will now determine […]
2023.02.03
PDF Axcelead Drug Discovery Partners Inc. (Head Office: Fujisawa, Kanagawa prefecture, CEO: Yoshinori Ikeura, “Axcelead DDP”) was selected as a Project Partner for Harvard Business School’s Immersive Field Course in last October and in this January, we hosted a team of 4 students from this course for approximately 1 week, offering them an experiential learning […]
2023.01.11
PDF Kaken Pharmaceutical Co., Ltd. (“Kaken”, Head Office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”, Head Office: Fujisawa, Kanagawa; President and CEO, Yoshinori Ikeura) announced that the companies have entered into an agreement to collaborate on creating innovative new drugs. As part of initiatives that […]
2022.12.27
PDF Tokyo and Fujisawa, Japan. December 27, 2022: ThinkCyte and Axcelead Drug Discovery Partners (DDP) announced a research partnership focused on developing new approaches to screen candidate drugs for treating human diseases. The partnership will combine Ghost Cytometry1), ThinkCyte’s AI-driven cell characterization and sorting technology, with Axcelead DDP’s phenotypic screening techniques2) and its diverse compound […]
2022.11.14
We’re delighted to announce that we have received official certification from 10x Genomics as a Certified Service Provider (CSP) of Visium, a spatial transcriptomics technology. The CSP status is awarded to providers who are able to deliver Visium services at a quality level that meets or exceeds a certain standard. Spatial transcriptomics enables simultaneous and […]
2022.11.02
PDF Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-Founders and Representative Directors: Hiroki Danno and Masakazu Fukuda) have entered into a collaborative research contract on gene expression analysis for drug-resistant cancer. In this collaborative research project, the companies will collaborate to discover specific cell […]
2022.10.20
The American College of Toxicology 2022 annual meeting will be held in Denver on November 13 to 16, and an international symposium between the US, EU and Japan will be held on Tuesday, November 15, 2022. Dr. Hideo Fukui, a Senior Director of Axcelead Drug Discovery Partners, Inc. will chair the session “Antibody-Drug Conjugates, Exosomes: […]
2022.10.05
PDF October 5, 2022 – Axcelead Drug Discovery Partners Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces a drug discovery collaboration with Acadia Pharmaceuticals Inc. (HQ: San Diego, CA, USA; hereinafter referred to as “Acadia”) to generate innovative medicines in the neuroscience area. The parties will engage in research programs to […]
2022.09.01
The PDF for the print Epigeneron Inc., (Headquarters: Chuo-ku, Tokyo, President: Tetsuya Mishima, “Epigeneron”) and Axcelead Drug Discovery Partners, Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture, President: Yoshinori Ikeura, “Axcelead DDP”) have entered into a master collaboration agreement on drug discovery research for novel drug targets. Epigeneron has a new and unique technology to identify novel […]
2022.08.19
PDF Perseus Proteomics Inc. (Head office: Meguro, Tokyo; President & CEO: Takuya Yokokawa, “Perseus”) and Axcelead Drug Discovery Partners Inc. (Head office: Fujisawa, Kanagawa; President & CEO: Yoshinori Ikeura, “Axcelead DDP”) today announced a collaboration in the antibody drug discovery support service. Perseus is generating antibody-based transformative therapeutics. Perseus has the proprietary and unique screening […]
2022.07.20
PDF TOKYO, JAPAN, 20 JULY 2022: ARCALIS Inc. (Head office: Kashiwa, Chiba; President & CEO: Tomoyuki Fujisawa; “ARCALIS”) and Axcelead Drug Discovery Partners Inc. (Head office: Fujisawa, Kanagawa; President & CEO: Yoshinori Ikeura; “Axcelead DDP”), both are subsidiary of Axcelead Inc. (Head office: Minato-ku, Tokyo; President & CEO: Tomoyuki Fujisawa; “Axcelead”), today announced a collaboration […]
2022.03.31
PDF Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as “Axcelead DDP”) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-founder, Representative Director: Hiroki Danno, Masakazu Fukuda; hereinafter referred to as “Knowledge Palette”) announce that both companies have entered into a collaborative research contract for establishment of a new evaluation […]
2022.01.17
The PDF for the print To Establish a Platform for the Efficient and High-quality Drug Discovery Aiming to Resolve Social Issues by Reducing Medical Costs On January 11th, IP Generator, Inc. (hereafter “IPG”), Axcelead, Inc. (hereafter “Axcelead”) and Axcelead Drug Discovery Partners, Inc. (hereafter “Axcelead DDP”) (those three companies are collectively called “Parties”) have signed […]
2021.12.15
Supporting optimization of product development and manufacturing with automation and quality assessment Tokyo, December 15, 2021 — Hitachi, Ltd. (TSE:6501, “Hitachi”) and Axcelead Drug Discovery Partners Inc. (“Axcelead DDP”) announced today that they launch a manufacturing process development support service for cell therapy and gene therapy from December 16.This service enables evaluation of cell quality […]
2021.11.25
Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has supported 24 research projects aiming at new drug development in an infrastructure program for “Drug Discovery Seeds Development ” since 2017. This program is one of initiatives in AMED to incubate drug discovery seeds originated in academic research organizations. In this program, Axcelead DDP has worked as […]
2021.11.01
Tokyo, Japan, October ##, 2021 — xFOREST Therapeutics Co., Ltd. (Headquarter: Kamigyo-ku, Kyoto, Japan, President and CEO: Shunichi Kashida, “xFOREST”), Axcelead Drug Discovery Partners Inc. (Headquarter: Fujisawa, Kanagawa, President: Yoshinori Ikeura, “Axcelead DDP”), and Kyowa Kirin Co., Ltd. (Headquarter: Chiyoda-ku, Tokyo, TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announce that the three companies have […]
2021.10.25
We are pleased to announce that Axcelead Drug Discovery Partners Inc., (Headquarters: Fujisawa, Kanagawa, JAPAN, CEO: Yoshinori Ikeura, hereinafter “Axcelead DDP”) will participate as a joint research institution to support “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan” led by the National Cancer Center Hospital East (Location: […]
2021.10.18
Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President, CEO: Yoshinori Ikeura; Axcelead) announces that the company has strengthened the platforms including high-throughput screening (HTS), high-throughput ADME (metabolism & pharmacokinetics) and TOX (safety) studies (HT-ADMET), based on a comprehensive business transfer agreement with a major Japanese pharmaceutical company (hereinafter, referred to as “the pharmaceutical company”). […]
2021.01.08
On January 7, the Japanese government declared State of Emergency to prevent the spread of COVID-19 pandemic for the Tokyo metropolitan area including Kanagawa Prefecture. Based on the Guidelines for the State of Emergency from the government, under strict countermeasures against infectious of COVID-19 Axcelead continue to work on the projects. If you have any […]
2020.12.10
Inhibition of PKCtheta as a therapeutic target has the potential to treat multiple inflammatory diseases Los Altos, California, USA and Fujisawa, Kanagawa, Japan – Dec. 10, 2020 – Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, and Axcelead Drug Discovery Partners, Inc. (Axcelead), a Japanese solution provider in drug discovery research, […]
2020.10.02
Tokyo, Japan, October 2, 2020 —Axcelead Drug Discovery Partners Inc.（Axcelead, President: Yoshinori Ikeura）and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announce that the companies have started collaboration on the development of innovative small-molecule drugs based on a novel drug discovery technology platform. By integrating Axcelead ‘s broad range of small-molecule […]
2020.06.17
June 29,2020- Otsuka Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Makoto Inoue; Otsuka Pharmaceutical) and Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President: Yoshinori Ikeura; Axcelead) announce a collaborative drug discovery research using the Axcelead Hit-identified Target (A-HiT) project* in the area of central nervous system diseases. Axcelead is the first comprehensive integrated […]
2019.10.01
Enter a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug delivery technology Contribute to maximizing R&D pipeline value though providing a new modality PassPort Technologies, Inc. (President and CEO: Tomoyuki Fujisawa, California, USA) (PPTI) and Axcelead Drug Discovery Partners Co., Ltd. (President: Yoshinori Ikeura, Fujisawa, […]
2019.07.10
To enhance the Process of Research and Development of Drug Candidates Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions. By combining Fujifilm’s iPSC-derived […]
2019.04.01
April 1, 2019 – Whiz Partners Inc. (hereinafter, “Whiz”), headquartered in Minato Ward, Tokyo, announced that it has completed an investment-in-kind to the “Drug Discovery Gateway Investment Limited Partnership” (hereinafter, “DDG Fund”) of issued Axcelead Drug Discovery Partners Inc. (hereinafter, “Axcelead”) shares held by Takeda Pharmaceutical Co., Ltd. (hereinafter, “Takeda”), headquartered in Chuo Ward, Osaka. […]
2018.10.17
Fujisawa, Japan and Dublin, Ireland, October 4, 2018 – Axcelead Drug Discovery Partners, Inc.(hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. […]
2018.08.03
We are pleased to announce that Axcelead Drug Discovery Partners Inc. (“Axcelead”) preparation to become a company independent from Takeda Pharmaceutical Company Limited (“Takeda”) as a core company of “Drug Discovery Gateway Investment Limited Partnership” (“DDG Fund”). Under the terms of the agreement between Takeda and Japan-based Alternative Asset Management Firm, Whiz Partners, Inc. (“Whiz”), […]
2018.05.30
We are pleased to announce that Axcelead Drug Discovery Partners, Inc. (Yoshinori Ikeura, President; Headquarters: Fujisawa-shi, Kanagawa, Japan; hereinafter referred to as “Axcelead”) and Leiden Experts on Advanced Pharmacokinetics & Pharmacodynamics Consultants BV (Henk-Jan Drenth, Managing Director; Headquarters: Leiden, the Netherlands; hereinafter referred to as “LAP&P”) decided to develop a business partnership for services provided […]
